Bringing Maine researchers together to identify solutions to opioid epidemic in Maine

NewsGuard 100/100 Score

The MDI Biological Laboratory and the University of New England (UNE) are bringing Maine researchers together to discuss how they can collaborate to identify solutions to the opioid epidemic in Maine.

In a first step toward this goal, the institution will hold a panel discussion on the opioid crisis at the upcoming 46th Maine Biological and Medical Sciences Symposium (MBMSS), an annual statewide gathering at which students and scientists have the opportunity to network, collaborate, exchange ideas and share research results.

The panel discussion, entitled "The Science Behind the Opioid Crisis," will be led by Karen L. Houseknecht, Ph.D., associate provost for research and scholarship at UNE. As a professor of pharmacology, Houseknecht leads a National Institutes of Health (NIH)-funded research program that studies the pharmacology of psychiatric medications and emerging drugs of abuse. She is part of a multi-investigator, NIH-funded project to develop safer medications for the treatment of chronic pain.

An audience discussion on the scientific resources that are being devoted to the opioid crisis will follow the panel discussion.

The rate of opioid-related overdose deaths in Maine is nearly double the national rate and the state ranks among the top 10 in the rate of opioid-related overdose deaths, according to the National Institute on Drug Abuse.

The panelists will be Ian D. Meng, Ph.D., and Leslie Ochs, Pharm.D., Ph.D., M.S.P.H., of UNE, and Elissa J. Chesler, Ph.D., and Vivek Kumar, Ph.D., of The Jackson Laboratory in Bar Harbor. The topics will include the roles played by genetics, pain and prescribing practices in the development of substance abuse, and the use of the mouse as a platform for addiction studies.

Maine is one of many states with federal IDeA (Institutional Development Award) funding that are prioritizing research focused on reducing the burden of opioid addiction, according to the National Institute of General Medical Sciences, which administers the IDeA program. The program was established to enhance biomedical research in the 23 states and Puerto Rico that have historically had low success rates for grant funding.

Many of the IDeA states include rural regions that have been hard hit by the opioid crisis.

"The National Institutes of Health encourages those who receive IDeA funding to share research results widely across institutions and states," said Jane E. Disney, Ph.D., director of education at the MDI Biological Laboratory. "Including this session on opioid research in our annual symposium is an example of our commitment to increasing knowledge about this important topic in Maine."

The panel discussion is expected to serve as a platform for a future symposium on the science behind the opioid crisis, she added.

"We know we have the scientific resources here in Maine to make real progress in addressing the opioid crisis," Houseknecht said. "Our goal is to bring researchers and health care professionals from across the state together to build collaborative partnerships to address the multi-faceted problem of substance abuse in an inter-disciplinary, intra-professional way."

Approximately 200 people are registered for the April 26-27 symposium, which was established in 1975 as a forum for scientists from a range of biological and biomedical sciences disciplines. Traditionally, it has also focused on supporting student research at the undergraduate and graduate levels and growing Maine's research capacity.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers elucidate how gene mutation mechanism causes autism